A new batch of neflamapimod capsules led to increased plasma drug concentrations and demonstrated improvement (p<0.001 vs. old capsules; ...
Protagonist Therapeutics (PTGX) announced topline results from ANTHEM-UC, a Phase 2b study of icotrokinra, the first investigational targeted ...
Pliant Therapeutics discontinues Phase 2b trial of bexotegrast for idiopathic pulmonary fibrosis due to safety concerns, but ...
Clinical Trials Arena on MSN4d
Beckley Psytech completes subjects’ enrolment for Phase IIb trial of TRD therapyBeckley Psytech has completed subject enrolment for the core stage of the global Phase IIb clinical trial of patent-protected ...
Pliant Therapeutics shares were halted in early morning trading after falling 25% to $2.57, after the company said it is discontinuing a phase 2b trial for bexotegrast in patients with idiopathic ...
Topline results from the core stage of the Phase 2b clinical trial are expected in mid-2025. “We are impressed by the Beckley Psytech team’s execution of the Phase 2b clinical trial of BPL-003 ...
Eradivir, a clinical-stage small molecule immunotherapy biotech company, announced it has begun a Phase 2 challenge study with its antiviral therapeutic, EV25. The study will provide safety and ...
“The initiation of our Phase 2b isomyosamine trial marks an important milestone in our mission to develop a novel science for immuno-metabolic regulation and increased longevity,” said ...
Topline results continue to be expected in the first half of 2025 NEW HAVEN, Conn., Feb. 25, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback